Boston Scientific vs Zoetis

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (78 vs 79)
Boston Scientific logo

Boston Scientific

LeaderHealthcare Tech

Enterprise

Marlborough MA cardiac devices leader (NYSE: BSX) $16.7B FY2024 revenue (+18%); Farapulse PFA ablation fastest-growing EP device, WATCHMAN FLX 70%+ LAAC share, competing with Abbott and Medtronic.

AI VisibilityBeta
Overall Score
B78
Category Rank
#42 of 596
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
79
Perplexity
81
Gemini
75

About

Boston Scientific Corporation is a Marlborough, Massachusetts-based global medical device company — publicly traded on the New York Stock Exchange (NYSE: BSX) as an S&P 500 Health Care component — developing and commercializing medical devices for minimally invasive diagnosis and treatment of cardiovascular disease, cardiac rhythm management, electrophysiology, urology, endoscopy, and neuromodulation through approximately 48,000 employees in 130 countries. In fiscal year 2024, Boston Scientific reported revenues of $16.7 billion (+18% year-over-year) — driven by the Farapulse pulsed field ablation (PFA) system for atrial fibrillation treatment, WATCHMAN FLX left atrial appendage closure (LAAC) device, and Rhythmia Ultra high-density cardiac mapping — making Boston Scientific the fastest-growing large-cap medical device company and one of the strongest organic growth stories in healthcare. CEO Mike Mahoney has executed acquisitions and organic R&D investment to build a diverse cardiovascular and electrophysiology portfolio: the 2023 acquisition of Apollo Endosurgery ($615 million, flexible endoscopic stapling for minimally invasive procedures) and the 2022 acquisition of Lumenis (surgical laser systems) expanded Boston Scientific beyond the cardiac core. Boston Scientific's strongest 2024 growth driver — Farapulse (pulsed field ablation) — achieved rapid adoption as a new standard-of-care in atrial fibrillation ablation by delivering shorter procedure times (2-hour PFA versus 4-hour radiofrequency ablation) and improved safety profile compared to traditional thermal ablation methods.

Full profile
Zoetis logo

Zoetis

LeaderHealthcare Tech

Animal Health

Zoetis (ZTS) reported ~$9.1B revenue in FY2024. World's largest animal health company developing medicines, vaccines, and diagnostics for companion animals and livestock. HQ: Parsippany, NJ.

AI VisibilityBeta
Overall Score
B79
Category Rank
#32 of 596
AI Consensus
66%
Trend
stable
Per Platform
ChatGPT
81
Perplexity
73
Gemini
84

About

Zoetis Inc. is the world's largest animal health company, developing, manufacturing, and commercializing medicines, vaccines, diagnostics, and other technologies for companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry, fish). Spun off from Pfizer in 2013, Zoetis has maintained its position as the global leader in animal health with approximately 300 product lines serving veterinarians, livestock producers, and pet owners in over 100 countries.

Full profile

AI Visibility Head-to-Head

78
Overall Score
79
#42
Category Rank
#32
73
AI Consensus
66
stable
Trend
stable
79
ChatGPT
81
81
Perplexity
73
75
Gemini
84
83
Claude
73
72
Grok
84

Key Details

Category
Enterprise
Animal Health
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Zoetis
Animal Health

Integrations

Only Boston Scientific
Boston Scientific is classified as company. Zoetis is classified as company (part of Pfizer).

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.